BRAF Analyte Control

BRAF V600E Analyte Control consists of two cores negative and positive for expression of BRAF V600E.

This provides a cost effective means on controlling for BRAF V600E in immunohistochemistry.


Introduction to BRAF

B-Raf proto-oncogene is a gene encoding the BRAF protein belonging to the RAF family of serine/threonine protein kinases. This protein regulates the MAP kinase/ERK signalling pathway, which influences cell division, migration and differentiation1.


V600E is a mutation of the BRAF gene in which valine is substituted by glutamic acid at amino acid 600. The negative charge of the glutamic acid mimics the phosphorylation of T599 threonine and S602 serine, causing an increase in basal BRAF activity. This mutation is therefore a key driver in the pathophysiology of a number of cancers, including melanoma, colorectal cancer and non-small cell lung cancer2.​


​BRAF V600E mutations have been found in several types of cancers such as melanoma, papillary thyroid carcinoma and colorectal adenocarcinoma with a frequency of approximately 60%, 40% and 12% respectively3. Additionally, studies have shown that the prevalence of BRAF mutation in lung carcinoma is approximately 2-4%4. ​

  1. BMC Cancer. 2020; 20(1):368.​
  2. Int J Mol Sci. 2021;22(7):3474.​
  3. Cancers (Basel). 2019; 11(9): 1262.​
  4. Trans. Lung Cancer Res. 2019; 8(3): 258-267.